The DOCK2 Knockout CAL-27 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human tongue squamous cell carcinoma line CAL-27. These cells carry a targeted disruption of the DOCK2 gene, which encodes a guanine nucleotide exchange factor (GEF) specific for Rac small GTPases. The polyclonal pool consists of a heterogeneous mixture of edited cells, providing a robust loss-of-function model for studying DOCK2-dependent processes without the clonal selection biases inherent in single-cell-derived lines. This product is designed for researchers investigating actin cytoskeletal dynamics, cell migration, and immune-related signaling in an oral cancer context.
The parental CAL-27 cell line is an epithelial carcinoma model established from a human squamous cell carcinoma of the tongue. It displays typical epithelial morphology and invasive behavior, making it a widely used system in oral cancer research, particularly for studies on tumor cell motility, invasion, and drug responsiveness. CAL-27 cells retain key signaling pathways relevant to carcinoma progression, including those involving Rac GTPases and actin remodeling, which are critical for metastatic dissemination.
DOCK2 functions as a Rac-specific guanine nucleotide exchange factor, catalyzing the exchange of GDP for GTP on Rac1 to stimulate actin polymerization and cytoskeletal reorganization. Upon activation by upstream receptors such as chemokine receptors (e.g., CXCR4, CCR7) and the T cell receptor, DOCK2 forms complexes with ELMO1 and CRK, leading to Rac1-mediated activation of downstream effectors including PAK1 and the WAVE?CArp2/3 complex. This signaling axis orchestrates lamellipodia formation, cell polarization, and directed migration. Additionally, DOCK2 plays a pivotal role in immune cell function, linking chemokine sensing to lymphocyte homing and immune synapse assembly. Disruption of DOCK2 thus impairs Rac1 cycling, attenuating both basal and stimulated actin dynamics.
In the context of CAL-27 oral carcinoma cells, DOCK2 knockout is particularly relevant for dissecting mechanisms underlying cancer cell invasion and metastasis. Aberrant Rac signaling is frequently associated with enhanced motility and invasiveness in head and neck cancers, and DOCK2 has been implicated in the migration of various cancer cell types. Loss of DOCK2 in this background may reveal dependencies on DOCK2-Rac1 signaling for processes such as chemotaxis and tissue infiltration, offering a platform for studying the transition from localized tumor to metastatic disease. Moreover, given DOCK2’s role in immunodeficiency, this model can be adapted to explore cross-talk between immune evasion and cancer progression.
Researchers can employ these polyclonal knockout cells in a range of functional assays, including wound healing migration assays, Transwell invasion assays, and F-actin immunofluorescence to quantify cytoskeletal changes. Rac1 activation status can be assessed via pull-down assays, while downstream phospho-signaling can be monitored by western blotting. This model is also suitable for drug screening campaigns aimed at identifying inhibitors of cell motility or Rac pathway components. By providing a versatile DOCK2-deficient background in an oral carcinoma line, the product enables systematic exploration of DOCK2??s contributions to cancer cell biology and therapeutic resistance. For further details or to discuss custom applications, please contact Ascent Research.
